ストックスクリーナーアプリを入手
26.97
2.67%
-0.74
前日終値:
$27.71
開ける：
$27.44
24時間の取引高:
2.48M
Relative Volume:
1.30
時価総額：
$4.45B
収益：
$1.51B
当期純損益:
$333.35M
株価収益率:
13.83
EPS:
1.95
ネットキャッシュフロー:
$315.22M
1週間 パフォーマンス:
-9.92%
1か月 パフォーマンス:
-1.68%
6か月 パフォーマンス:
-19.28%
1年 パフォーマンス:
+1.54%
1日の値動き範囲:
$26.93
$27.68
1週間の範囲:
$25.16
$28.65
52週間の値動き範囲:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
ALKS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
26.97 | 4.45B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
Baird Financial Group Inc. Purchases New Shares in Alkermes plc $ALKS - MarketBeat
Alkermes appoints Joshua Reed as new CFO effective Monday By Investing.com - Investing.com Australia
Investors Purchase Large Volume of Alkermes Call Options (NASDAQ:ALKS) - MarketBeat
Alkermes says on Sept 9, unit granted Amneal rights to sell generic version of VivitrolSEC filing - MarketScreener
Alkermes Appoints Joshua Reed as New CFO - TipRanks
Alkermes plc Appoints Joshua Reed as Chief Financial Officer, Effective Date Is September 15, 2025 - MarketScreener
Alkermes appoints Joshua Reed as new CFO effective Monday - Investing.com
Alkermes (ALKS) Appoints Joshua Reed as New CFO - GuruFocus
30-Year Biotech Finance Veteran Joshua Reed Joins Alkermes as CFO After Bristol Myers Leadership - Stock Titan
While Shareholders of Alkermes (NASDAQ:ALKS) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - Eastern Progress
Fred Alger Management LLC Takes $1.24 Million Position in Alkermes plc $ALKS - MarketBeat
AQR Capital Management LLC Sells 279,276 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $35.00 - MarketBeat
Alkermes' (ALKS) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Potential Impact on Alkermes (ALKS) from RFK Jr.'s Possible Depa - GuruFocus
How RFK Jr.'s Potential Exit Could Benefit Alkermes (ALKS) - GuruFocus
Alkermes (NASDAQ:ALKS) Hits New 52-Week LowTime to Sell? - MarketBeat
December 2026 Options Now Available For Alkermes (ALKS) - Nasdaq
Can Alkermes plc stock outperform in a bear market2025 Risk Factors & Stepwise Trade Signal Guides - Lancaster City Council
HC Wainwright & Co. Reiterates Neutral Rating for ALKS | ALKS St - GuruFocus
Alkermes Announces Positive Phase 2 Study Results - MSN
Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Alkermes plc $ALKS Shares Acquired by Canada Pension Plan Investment Board - MarketBeat
Is Alkermes plc stock showing strong momentumJuly 2025 Spike Watch & Reliable Breakout Forecasts - 뉴스영
Alkermes stock hits 52-week low at 25.31 USD By Investing.com - Investing.com Canada
Alkermes (ALKS) Reports Promising Results from Phase 2 Narcoleps - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com Canada
Takeda and Alkermes share OX2R drug data for narcolepsy - Yahoo Finance
Alkermes stock hits 52-week low at 25.31 USD - Investing.com
Alkermes (ALKS) Shows Progress in Narcolepsy Study, Faces Invest - GuruFocus
Alkermes : ALKS World Sleep 2025 Prepared Remarks 9 8 2025 FINAL - MarketScreener
Transcript : Alkermes plcShareholder/Analyst Call - MarketScreener
Alkermes stock maintains Buy rating at Stifel following sleep disorder data - Investing.com Nigeria
Real Time Data Flags Unusual Activity in Alkermes plc2025 Investor Takeaways & Daily Oversold Bounce Ideas - beatles.ru
Alkermes plc $ALKS Position Trimmed by Palo Alto Investors LP - MarketBeat
Alkermes (ALKS) Reports Promising Phase 2 Results for Narcolepsy Treatment Alixorexton - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug - Investing.com
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study - MarketScreener
Alkermes presents detailed positive results from Vibrance-1 Phase 2 Study of Alixorextin in patients with narcolepsy type 1 - MarketScreener
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 - Yahoo Finance
Alkermes (NASDAQ:ALKS) Trading 7.2% Higher Following Analyst Upgrade - MarketBeat
337,603 Shares in Alkermes plc $ALKS Acquired by MPM Bioimpact LLC - MarketBeat
Alkermes plc $ALKS Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Does Alkermes plc show high probability of reboundWeekly Trade Recap & Consistent Income Trade Recommendations - Newser
When is the best time to exit Alkermes plcWeekly Risk Summary & Daily Oversold Bounce Ideas - Newser
Can swing trading help recover from Alkermes plc lossesRate Cut & AI Enhanced Trading Signals - Newser
PDT Partners LLC Increases Stock Position in Alkermes plc $ALKS - MarketBeat
Visual analytics tools that track Alkermes plc performanceProfit Target & Free Growth Oriented Trading Recommendations - Newser
Can Alkermes plc maintain sales growthJuly 2025 Short Interest & Weekly High Return Stock Opportunities - خودرو بانک
Is Alkermes plc in a long term uptrendJuly 2025 News Drivers & Stepwise Trade Execution Plans - خودرو بانک
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
1.33%
0.04%
大文字化:
|
ボリューム (24 時間):